Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 5/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4373913 | 0.80 | — | — | |
| SCHEMBL4139553 | 0.80 | — | — | |
| SCHEMBL4374793 | 0.80 | — | — | |
| SCHEMBL179147 | 0.75 | ADRB2 (0.49) | ADRB2ADRB1ADRB3CYP2D6PTGS1 | |
| SCHEMBL22519414 | 0.75 | ADRB2 (0.41) | ADRB2ADRB1ADRB3CYP2D6MEN1 | |
| SCHEMBL11159331 | 0.74 | KDM4E (0.48) | ADRB2ADRB1ADRB3CYP2D6PTGS1 | |
| SCHEMBL23976280 | 0.73 | ADRB2 (0.53) | ADRB2ADRB1ADRB3CYP2D6PTGS1 | |
| Acetone SCHEMBL10800590 | 0.72 | ADRB2 (0.42) | ADRB2ADRB1ADRB3CYP2D6MEN1 | |
| SCHEMBL9759886 | 0.70 | ADRB2 (0.50) | ADRB2ADRB1ADRB3CYP2D6PTGS1 | |
| SCHEMBL4845727 | 0.70 | ADRB2 (0.54) | ADRB2ADRB1ADRB3CYP2D6PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303494-A1 | BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303494-A1 | BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | CD274, PDCD1, PDCD1LG2 | ADRB2 1642/4885ADRB1 577/4885ADRB3 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.